

Estimated Vaccination Coverage With Selected Vaccines Among Adolescents Aged 13-17* Years by Age at Interview - National Immunization Survey-Teen, 2011

| Vaccines | Age at Interview (years) | | | | | |
|--|--|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------|
| | 13 | 14 | 15 | 16 | 17 | 2011 |
| | (n = 4,763) % (95% CI) [†] | (n = 4,842) % (95% CI) | (n = 4,750) % (95% CI) | (n = 4,774) % (95% CI) | (n = 4,435) % (95% CI) | (n = 23,564) % (95% CI) |
| ≥ 2 doses MMR[§] | 92.0(±1.3) | 91.8(±1.5) | 90.6(±1.7) | 91.8(±1.5) | 89.2(±1.7) | 91.1(±0.7) |
| ≥ 3 doses Hepatitis B | 93.7(±1.2) | 93.5(±1.3) | 91.8(±1.8) | 92.1(±1.5) | 90.4(±1.5) | 92.3(±0.7) |
| Varicella | | | | | | |
| History of varicella disease [¶] | 22.1(±2.1) | 29.6(±2.2) | 36.0(±2.6) | 43.8(±2.6) | 51.8(±2.6) | 36.6(±1.1) |
| ≥ 1 dose vaccine if had no history of disease | 96.4(±1.1) | 96.2(±1.3) | 90.4(±3.1) | 90.3(±2.4) | 84.7(±3.0) | 92.3(±1.0) |
| ≥ 2 doses vaccine if had no history of disease | 74.3(±2.4) | 73.5(±2.6) | 67.0(±3.4) | 63.9(±3.4) | 57.5(±3.9) | 68.3(±1.4) |
| History of disease or received ≥ 2 doses varicella vaccination | 80.0(±1.9) | 81.3(±1.9) | 78.9(±2.4) | 79.7(±2.1) | 79.5(±2.2) | 79.9(±1.0) |
| Td or Tdap^{**} | | | | | | |
| ≥ 1 dose Td or Tdap since age 10 years | 83.9(±1.8) | 85.2(±1.7) | 86.2(±2.0) | 86.7(±1.7) | 84.2(±1.9) | 85.3(±0.8) |
| ≥ 1 dose Tdap since age 10 years | 81.0(±2.0) | 80.6(±2.0) | 79.8(±2.2) | 78.3(±2.0) | 70.8(±2.4) | 78.2(±0.9) |
| ≥1 dose MenACWY^{††} | 71.4(±2.1) | 72.0(±2.2) | 71.1(±2.6) | 69.5(±2.4) | 68.5(±2.4) | 70.5(±1.0) |
| HPV^{§§} | | | | | | |
| FEMALE | | | | | | |
| ≥ 1 dose | 41.6(±3.6) | 45.5(±3.6) | 56.4(±3.8) | 59.2(±3.7) | 62.8(±3.4) | 53.0(±1.7) |
| ≥ 3 doses | 22.9(±2.9) | 29.2(±3.2) | 37.8(±4.1) | 40.0(±3.7) | 44.5(±3.7) | 34.8(±1.6) |
| 3 dose series completion ^{¶¶} | 63.6(±5.7) | 72.1(±5.0) | 70.8(±5.0) | 71.0(±5.0) | 74.0(±4.9) | 70.7(±2.3) |
| MALE | | | | | | |
| ≥ 1 dose | 9.8(±2.4) | 8.2(±2.0) | 7.4(±1.7) | 9.8(±2.7) | 6.2(±1.3) | 8.3(±1.0) |
| ≥ 3 doses | 1.6(±0.8) | 1.8(±1.1) | 0.9(±0.4) | 1.3(±0.6) | 1.0(±0.5) | 1.3(±0.3) |
| 3 dose series completion ^{¶¶} | 32.4(±14.1) | 35.7(±16.6) | 21.6(±10.6) | 21.1(±11.8) | 32.0(±12.0) | 28.1(±6.5) |

* Adolescents in the 2011 NIS-Teen were born during January 1993-February 1999. Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. National estimates do not include adolescents living in the U.S. Virgin Islands (i.e., St. Croix, St. Thomas, and St. John) (n=484).

[†] Estimate presented as point estimate (%) ± 95% confidence interval (CI).

[§] ≥2 doses of measles, mumps, and rubella vaccine.

[¶] By parent/guardian report or provider records.

^{**} ≥1dose of tetanus and diptheria toxoid vaccine (Td), tetanus toxoid, reduced diptheria toxoid, and acellular pertussis (Tdap), or tetanus-unknown type vaccine.

^{††} ≥1 dose of meningococcal conjugate vaccine or meningococcal-unknown type vaccine.

^{§§} ≥1dose of human papillomavirus vaccine, either quadrivalent or bivalent. Percentages reported among females (n=11,236) and males (n=12,328). Some adolescents may have received more than the three recommended HPV doses.

^{¶¶} Percent of females and males who received three doses among those who had at least one HPV dose and at least 24 weeks between the first dose and the interview date.